<?xml version='1.0' encoding='utf-8'?>
<document id="30713247"><sentence text="Optimization of Individual Pharmacotherapy Based on Multiple Evaluations of Patient Data." /><sentence text="To date, limited drug information is available for the individual optimization of pharmacotherapy" /><sentence text=" The author attempted multiple evaluations of patient data on factors related to the pharmacokinetics, drug efficacy, and adverse reactions observed in clinical settings" /><sentence text=" Through the clinical studies, drug information on the individual optimization of pharmacotherapy needed by health professionals including physicians and pharmacists was identified" /><sentence text=" Major findings were: 1) Cachectic cancer patients had high plasma concentrations of oxycodone via the reduction of CYP3A activity"><entity charOffset="85-94" id="DDI-PubMed.30713247.s5.e0" text="oxycodone" /></sentence><sentence text=" The metabolic reduction in cachectic cancer patients was potentially related to the elevated serum level of interleukin-6" /><sentence text=" 2) Dopamine receptor D2 (DRD2) genetic mutations and being female led to poor antiemetic efficacy of the treatment of opioid-induced nausea in prochlorperazine-treated patients"><entity charOffset="4-12" id="DDI-PubMed.30713247.s7.e0" text="Dopamine" /><entity charOffset="144-160" id="DDI-PubMed.30713247.s7.e1" text="prochlorperazine" /><pair ddi="false" e1="DDI-PubMed.30713247.s7.e0" e2="DDI-PubMed.30713247.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30713247.s7.e0" e2="DDI-PubMed.30713247.s7.e1" /></sentence><sentence text=" The opioid receptor Î¼1 (OPRM1) wild genotype in addition to being female and having high plasma concentrations of prochlorperazine increased prolactin secretion during oxycodone treatment"><entity charOffset="5-11" id="DDI-PubMed.30713247.s8.e0" text="opioid" /><entity charOffset="115-131" id="DDI-PubMed.30713247.s8.e1" text="prochlorperazine" /><entity charOffset="169-178" id="DDI-PubMed.30713247.s8.e2" text="oxycodone" /><pair ddi="false" e1="DDI-PubMed.30713247.s8.e0" e2="DDI-PubMed.30713247.s8.e0" /><pair ddi="false" e1="DDI-PubMed.30713247.s8.e0" e2="DDI-PubMed.30713247.s8.e1" /><pair ddi="false" e1="DDI-PubMed.30713247.s8.e0" e2="DDI-PubMed.30713247.s8.e2" /><pair ddi="false" e1="DDI-PubMed.30713247.s8.e1" e2="DDI-PubMed.30713247.s8.e1" /><pair ddi="false" e1="DDI-PubMed.30713247.s8.e1" e2="DDI-PubMed.30713247.s8.e2" /></sentence><sentence text=" 3) Rheumatoid arthritis patients with a genetic mutation of ATP-binding cassette subfamily B member 1 (ABCB1) had high plasma concentrations of tacrolimus and its 13-O-demethylate"><entity charOffset="145-155" id="DDI-PubMed.30713247.s9.e0" text="tacrolimus" /><entity charOffset="164-180" id="DDI-PubMed.30713247.s9.e1" text="13-O-demethylate" /><pair ddi="false" e1="DDI-PubMed.30713247.s9.e0" e2="DDI-PubMed.30713247.s9.e0" /><pair ddi="false" e1="DDI-PubMed.30713247.s9.e0" e2="DDI-PubMed.30713247.s9.e1" /></sentence><sentence text=" The ABCB1 genetic mutation and associated high plasma concentration of tacrolimus decreased kidney function"><entity charOffset="72-82" id="DDI-PubMed.30713247.s10.e0" text="tacrolimus" /></sentence><sentence text=" 4) Chronic inflammation increased the plasma voriconazole concentration via its poor metabolism, whereas it did not alter the plasma itraconazole concentration"><entity charOffset="46-58" id="DDI-PubMed.30713247.s11.e0" text="voriconazole" /><entity charOffset="134-146" id="DDI-PubMed.30713247.s11.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.30713247.s11.e0" e2="DDI-PubMed.30713247.s11.e0" /><pair ddi="false" e1="DDI-PubMed.30713247.s11.e0" e2="DDI-PubMed.30713247.s11.e1" /></sentence><sentence text=" Although co-administration of prednisolone did not affect the plasma concentration of triazole antifungals, it weakly increased voriconazole metabolism"><entity charOffset="31-43" id="DDI-PubMed.30713247.s12.e0" text="prednisolone" /><entity charOffset="87-95" id="DDI-PubMed.30713247.s12.e1" text="triazole" /><entity charOffset="129-141" id="DDI-PubMed.30713247.s12.e2" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.30713247.s12.e0" e2="DDI-PubMed.30713247.s12.e0" /><pair ddi="false" e1="DDI-PubMed.30713247.s12.e0" e2="DDI-PubMed.30713247.s12.e1" /><pair ddi="false" e1="DDI-PubMed.30713247.s12.e0" e2="DDI-PubMed.30713247.s12.e2" /><pair ddi="false" e1="DDI-PubMed.30713247.s12.e1" e2="DDI-PubMed.30713247.s12.e1" /><pair ddi="false" e1="DDI-PubMed.30713247.s12.e1" e2="DDI-PubMed.30713247.s12.e2" /></sentence><sentence text=" 5) In breastfeeding women, the median milk/plasma concentration ratio of amlodipine was 0"><entity charOffset="74-84" id="DDI-PubMed.30713247.s13.e0" text="amlodipine" /></sentence><sentence text="85" /><sentence text=" However, the observed relative infant dose of amlodipine in most patients was less than 10%"><entity charOffset="47-57" id="DDI-PubMed.30713247.s15.e0" text="amlodipine" /></sentence><sentence text="" /></document>